4.5 Article

Mitral valve endothelial cells secrete osteoprotegerin during endothelial mesenchymal transition

Journal

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 98, Issue -, Pages 48-57

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2016.06.061

Keywords

Circulating marker; Endothelial to mesenchymal transition; Mitral valve prolapse; Valve endothelial cells; Valve interstitial cells

Funding

  1. Fondazione Gigi e Pupa Ferrari ONLUS
  2. Fondazione Umberto Veronesi [FUV]
  3. Italian Ministry of Health [RC2014 BIO61, RC2015 BIO30]
  4. National Institutes of Health [R01-HL131872, R01-HL119297]
  5. American Heart Association [15GRNT24810002]
  6. Valley Hospital Foundation

Ask authors/readers for more resources

Aims: Mitral valve prolapse (MVP) has a prevalence of 3% in the general population, affecting >176 million people worldwide. Despite this, little is known about the molecular and cellular mechanisms involved in the progression of MVP and surgical intervention is the only available option. In this study we investigated the role of osteoprotegerin (OPG) during endothelial to mesenchymal transition (EndMT) in MVP. Methods and results: VECs and VICs were isolated from posterior mitral valve leaflets of patients undergoing mitral valve repair (n = 25). Plasma was collected from 57 subjects (29 controls and 28 MVP patients). Overexpression of OPG during EndMT followed by autocrine effects characterised by reactive oxygen species increment and accelerated migration was documented. In addition, OPG increased VIC proliferation. Finally, OPG plasma levels were significantly higher in MVP patients compared to control subjects and the area under the ROC curve was 0.92. Conclusion: EndMT has been recognised as a possible pathological mechanism for MVP. For the first time, we report the involvement of OPG in cellular and molecular changes in MVP isolated cells. In addition, we detected elevated circulating OPG levels in MVP patients when compared to controls, which supports the hypothesis that OPG is involved in MVP development and progression. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available